You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202013808
Dec 20203206
Jan 20211201
Feb 20211807
Mar 202132013
Apr 20214205
May 20211104
Jun 2021005
Jul 2021007
Aug 20210011
Sep 2021006
Oct 202168028
Nov 202142019
Dec 20214807
Jan 20221803
Feb 20222804
Mar 20225805
Apr 20225207
May 202254010
Jun 202256013
Jul 20226003
Aug 20224006
Sep 20223008
Oct 20225405
Nov 202242012
Dec 20223803
Jan 20233605
Feb 20236202
Mar 20238205
Apr 20235805
May 20236609
Jun 20234009
Jul 202342010
Aug 20239004
Sep 20236806
Oct 20235604
Nov 20233803
Dec 202310803
Jan 20242202
Feb 20244005
Mar 202494012
Apr 202472011
May 20245603
Jun 20245709
Jul 20245604
Aug 20248109
Sep 202482010
Oct 202486011
Nov 20247008
Dec 20245607
Jan 20254807
Feb 20251209
Mar 2025006
Apr 2025006
May 2025009
Jun 20250010
Total25510409